RxDoctor Payments Data

Daniel Boykin, DO

Family Medicine · Myrtle Beach, SCNPI 1194380659

Payments from drug & device makers

$1,566in general payments, 2019–2025

Across 72 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$531
  • AbbVie$225
  • Lilly USA, LLC$153
  • AstraZeneca$138
  • GSK$127
  • Amgen$76
  • plus $316 from 11 others

What the payments were for

  • Food & beverage$1,566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,566 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$85,853
Medicare patients
429
Services billed
1,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$147,576
MounjaroTirzepatide127$132,117
JardianceEmpagliflozin74$89,113
EliquisApixaban60$72,548
FarxigaDapagliflozin Propanediol40$38,715
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$31,352
TrulicityDulaglutide20$27,819
RybelsusSemaglutide12$27,811
UbrelvyUbrogepant19$24,967
XareltoRivaroxaban14$19,289
Breo ElliptaFluticasone/Vilanterol16$9,788
LinzessLinaclotide12$6,343
Nebivolol Hcl77$5,239
Atorvastatin Calcium478$5,126
Losartan Potassium420$4,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$531$175,387152 claims
Lilly USA, LLCMounjaro, Trulicity$153$159,936147 claims
PfizerEliquis$69$72,54860 claims
GSKTrelegy Ellipta, Breo Ellipta$127$41,14045 claims
AstraZenecaFarxiga$138$38,71540 claims
AbbVieUbrelvy, Linzess, Synthroid$225$33,00468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →